Peptide-based cancer vaccines.
The application of molecularly defined vaccines composed of a limited number of tumor-specific T cell epitopes has resulted in protective antitumor T cell immunity in several mouse tumor models. The first encouraging results with such vaccines have been obtained in human beings. The development of the next generation of rationally designed vaccines that are both effective and safe for application in a clinical setting requires comparison of different modes of delivery of tumor-associated T cell epitopes in multiple epitope constructs.
Melief
C J
CJ
Department of Immunohaematology, University Hospital of Leiden, The Netherlands. ihbsecr@euronet.nl
Offringa
R
R
Toes
R E
RE
Kast
W M
WM
D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm; D000957:Antigens, Viral, Tumor; D019496:Cancer Vaccines / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology*; D000939:Epitopes; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D010455:Peptides / Q000276:immunology* / Q000378:metabolism; D011485:Protein Binding; D013601:T-Lymphocytes / Q000276:immunology
D000951:Antigens, Neoplasm; D000957:Antigens, Viral, Tumor; D019496:Cancer Vaccines; D000939:Epitopes; D015395:Histocompatibility Antigens Class I; D010455:Peptides